Improvement of cognitive dysfunction with high-dose rivastigmine

Psychosomatics

Volumn 51, Issue 1, 2010, Pages 89-90

  Politis, Antonios M ^a,b   Theleritis, Christos ^a   Passa, Maria ^a   Maillis, Antonios ^a   Papadimitriou, George N ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

QUETIAPINE; RIVASTIGMINE; SERTRALINE;

AGED; ALZHEIMER DISEASE; CASE REPORT; COGNITION; COGNITIVE DEFECT; DEPRESSION; DRUG DOSE ESCALATION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG MEGADOSE; DRUG WITHDRAWAL; FEMALE; HUMAN; LETTER;

EID: 75949110857     PISSN: 00333182     EISSN: None     Source Type: Journal    
DOI: 10.1176/appi.psy.51.1.89     Document Type: Letter

References (7)

1. Lemstra AW, Kuiper RB, Schmand B, et al: Identification of responders to rivastigmine: a prospective cohort study. Dement Geriatr Cogn Disord 2008; 25:60-66
2. American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, 4th Edition, Text Revision. Washington, DC, American Psychiatric Association, 2000
3. Politis AM, Mayer LS, Passa M, et al: Validity and reliability of the newlytranslated Hellenic Neuropsychiatric Inventory (H-NPI) applied to Greek outpatients with Alzheimer's disease: a study of disturbing behaviours among referrals to a memory clinic. Int J Geriatr Psychiatry 2004; 19:203-208
4. Yan-qi Lang, Xi-can Tang: Comparative studies of huperzine A, donepezil, and rivastigmine on brain acetylcholine, dopamine, norepinephrine, and 5-hydroxytryptamine levels in freely-moving rats. Acta Pharmacol Sinica 2006; 27:1127-1136
5. Blesa R, Bullock R, He Y, et al: Effect of butyrylcholinesterase genotype on the response to rivastigmine or donepezil in younger patients with Alzheimer's disease. Pharmacogenet Genomics 2006; 16:771-774
6. Winblad B, Grossberg G, Froligh L, et al: IDEAL: a 6-month, double-blind, placebocontrolled study of the first skin patch for Alzheimer's disease. Neurology 2007; 69(4; suppl 1):S14-22
7. Eskander MF, Nagykery NG, Leung EY, et al: Rivastigmine is a potent inhibitor of acetyl-and butyrylcholinesterase in Alzheimer plaques and tangles. Brain Res 2005; 1060:144-152